<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Crotalinae (pit viper) equine immune F(ab')2 antivenom: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Crotalinae (pit viper) equine immune F(ab')2 antivenom: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Crotalinae (pit viper) equine immune F(ab')2 antivenom: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="101634" href="/d/html/101634.html" rel="external">see "Crotalinae (pit viper) equine immune F(ab')2 antivenom: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="107352" href="/d/html/107352.html" rel="external">see "Crotalinae (pit viper) equine immune F(ab')2 antivenom: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52120391"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anavip</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F28118267"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antivenin</li></ul></div>
<div class="block doa drugH1Div" id="F28558002"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ce281ed-3f13-4a7c-99cd-c3759888af4f">North American pit viper envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>North American pit viper</b>
<b>envenomation:</b>
<b>Note:</b> Initiate therapy as soon as possible after a North American pit viper bite in patients exhibiting any signs of envenomation.</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>IV:</b> 10 vials; may repeat with an additional 10-vial dose every hour as needed for initial control until local signs of envenomation are not progressing, systemic symptoms are resolved, and coagulation and other laboratory parameters have normalized or are trending toward normal. There is no known maximum dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: <b>IV:</b> Once initial control is achieved, administer 4 vials as needed to suppress any re-emerging symptoms, including recurrent coagulopathies; monitor for at least 18 hours in a health care setting.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Clinical trials administered maintenance doses at 6-hour intervals for 3 doses. The longer plasma persistence time of F(ab')<sub>2</sub> antivenom levels (as compared to Fab antivenom [ie, CroFab]) may prevent recurrent venom effects (eg, delayed or recurrent hypofibrinogenemia and thrombocytopenia) (Boyer 2013).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990019"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987294"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F28558003"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F28558001"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="107352" href="/d/html/107352.html" rel="external">see "Crotalinae (pit viper) equine immune F(ab')2 antivenom: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Initiate therapy as soon as possible after a North American pit viper bite in patients exhibiting any signs of envenomation.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9ce281ed-3f13-4a7c-99cd-c3759888af4f">North American pit viper envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>North American pit viper envenomation:</b> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: IV: Ten vials; may repeat with an additional 10-vial dose every hour as needed for initial control until local signs of envenomation are not progressing, systemic symptoms are resolved, and coagulation and other laboratory parameters have normalized or are trending toward normal. There is no known maximum dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: IV: Once initial control is achieved, monitor for ≥18 hours in a health care setting; administer 4 vials as needed to suppress any reemerging symptoms, including recurrent coagulopathies.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090060"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090061"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F29835954"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (43%), skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (4%), skin blister (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (2%), chills (4%), headache (6%), insomnia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (6%), myalgia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain, flushing, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin or other tissue necrosis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (Ontiveros 2021)</p></div>
<div class="block coi drugH1Div" id="F28118310"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed within the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F28473325"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute hypersensitivity reactions: Derived from equine (horse) immune globulin F(ab’)<sub>2</sub> fragments; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to horse protein. Patients who have had previous treatment with <i>Crotalidae</i> immune F(ab’)<sub>2</sub> or other equine-derived antivenom/antitoxin may be at a higher risk for hypersensitivity reactions. However, the majority of early adverse reactions that occur following antivenom administration are <i>de novo</i> (reactions in individuals without prior exposure or sensitization) and are non-IgE mediated (Laustsen 2018). In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available (Campbell 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed serum sickness: Delayed serum sickness may occur, usually within 2 weeks; monitor patients with follow-up visits for signs and symptoms (eg, arthralgia, fever, myalgia, pruritus, rash, urticaria).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form related issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cresol: Product may contain small amounts of cresol resulting from the manufacturing process; local reactions and generalized myalgias may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Disease transmission: Product derived from equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease.</p></div>
<div class="block foc drugH1Div" id="F52120392"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anavip:  (1 ea) [contains cresol]</p></div>
<div class="block geq drugH1Div" id="F52120390"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F28558032"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Infuse IV over 60 minutes. Infuse at a rate of 25 to 50 mL/hour for the first 10 minutes, carefully monitoring for any allergic reactions. If no reactions occur, increase the infusion rate incrementally to 250 mL/hour until completion. Discontinue the infusion if any allergic reaction occurs and institute appropriate emergency treatment. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available during the infusion of an antivenom (Campbell 2014; Lavonas 2011). Reassess the risk to benefit ratio before continuing the infusion.</p></div>
<div class="block admp drugH1Div" id="F52614589"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: Infuse over 60 minutes. Infuse at a rate of 25 to 50 mL/hour for the first 10 minutes, carefully monitoring for any allergic reactions. If no reactions occur, increase the infusion rate incrementally to 250 mL/hour until completion. Discontinue the infusion if any allergic reaction occurs and institute appropriate emergency treatment. Immediate treatment (eg, epinephrine, corticosteroids, diphenhydramine) should be available during the infusion of an antivenom (Campbell 2014; Lavonas 2011). Reassess the risk to benefit ratio before continuing the infusion.</p></div>
<div class="block use drugH1Div" id="F28118269"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>North American pit viper</b>
<b>envenomation:</b> Management of adult and pediatric patients with North American pit viper envenomation (eg, North American rattlesnakes [genera <i>Crotalus</i> and <i>Sistrurus</i>], cottonmouths and copperheads [genus <i>Agkistrodon</i>] [Corbett 2017; Kanaan 2015]).</p></div>
<div class="block cyt drugH1Div" id="F28120438"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F28120435"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F28473207"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p>
<p style="text-indent:0em;margin-top:2em;">Available evidence suggests the main adverse pregnancy outcomes associated with a venomous snakebite (eg, fetal loss, placental abruption, preterm labor) are due to the direct effects of the toxin and resulting maternal illness. Antivenom administration in pregnancy should be considered when otherwise clinically indicated using a venom-specific approach, extended fetal and maternal monitoring, supportive care, and treatment of anaphylaxis if needed (Brown 2013; Kanaan 2015).</p></div>
<div class="block brc drugH1Div" id="F28473209"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if <i>Crotalidae</i> Immune F(ab’)<sub>2</sub> (Equine) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F28558034"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin (prior to administration and at regular intervals to gauge response to therapy and anticipate additional dosage requirement); size of bite area (repeat every 15 to 30 minutes); intake and output; signs and symptoms of anaphylaxis/allergy. Following the initial control of signs and symptoms, CBC, platelet counts, and clotting studies are evaluated at 6- to 8-hour intervals until patient is stable (Lavonas 2011). The manufacturer recommends monitoring patients in a health care setting for at least 18 hours following initial control of signs and symptoms.</p></div>
<div class="block pha drugH1Div" id="F28473334"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Contains venom-specific F(ab’)<sub>2</sub> fragments of immunoglobulin G (IgG) that bind and neutralize venom toxins of North American pit vipers (genera <i>Crotalus </i>and <i>Sistrurus </i>and genus <i>Agkistrodon</i>), facilitating redistribution away from target tissues and elimination from the body.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Anavip (Crotalidae immune F[ab’]<sub>2</sub> [equine]) originates from horses immunized with the venom from the pit vipers <i>Bothrops asper</i> and <i>Crotalus simus</i> (formerly<i> Crotalus durissus</i>).</p></div>
<div class="block phk drugH1Div" id="F28557941"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 3.3 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~5.5 days</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  ANAVIP (Crotalidae Immune F[ab']2 [Equine]) [prescribing information]. Franklin, TN: Rare Disease Therapeutics Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140. doi:10.1002/bdra.10007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23948058">
<a name="23948058"></a>Boyer LV, Chase PB, Degan JA, et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')<sub>2</sub> antivenoms. <i>Toxicon</i>. 2013;74:101-108. doi:10.1016/j.toxicon.2013.07.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/23948058/pubmed" id="23948058" target="_blank">23948058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298218">
<a name="23298218"></a>Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila).</i> 2013;51(1):3-15. doi:10.3109/15563650.2012.760127<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/23298218/pubmed" id="23298218" target="_blank">23298218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25466802">
<a name="25466802"></a>Campbell RL, Li JT, Nicklas RA, Sadosty AT; Members of the Joint Task Force; Practice Parameter Workgroup. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter. <i>Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608. doi:10.1016/j.anai.2014.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/25466802/pubmed" id="25466802" target="_blank">25466802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28411931">
<a name="28411931"></a>Corbett B, Clark RF. North American snake envenomation. <i>Emerg Med Clin North Am</i>. 2017;35(2):339-354. doi:10.1016/j.emc.2016.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/28411931/pubmed" id="28411931" target="_blank">28411931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26433731">
<a name="26433731"></a>Kanaan NC, Ray J, Stewart M, et al. Wilderness Medical Society practice guidelines for the treatment of pitviper envenomations in the United States and Canada. <i>Wilderness Environ Med</i>. 2015;26(4):472-487. doi:10.1016/j.wem.2015.05.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/26433731/pubmed" id="26433731" target="_blank">26433731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29534892">
<a name="29534892"></a>Laustsen AH, María Gutiérrez J, Knudsen C, et al. Pros and cons of different therapeutic antibody formats for recombinant antivenom development. <i>Toxicon</i>. 2018;146:151-175. doi:10.1016/j.toxicon.2018.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/29534892/pubmed" id="29534892" target="_blank">29534892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21291549">
<a name="21291549"></a>Lavonas EJ, Ruha AM, Banner W, et al; Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. <i>BMC Emerg Med</i>. 2011;11:2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/21291549/pubmed" id="21291549" target="_blank">21291549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33155844">
<a name="33155844"></a>Ontiveros S, Clark RF, Minns AB. Acute hypersensitivity reaction from administration of crotalidae immune F(ab')2 antivenom. <i>Clin Toxicol (Phila)</i>. 2021;59(7):676. doi:10.1080/15563650.2020.1837386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/crotalinae-pit-viper-equine-immune-f-ab-2-antivenom-drug-information/abstract-text/33155844/pubmed" id="33155844" target="_blank">33155844</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 101422 Version 63.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
